Previous 10 | Next 10 |
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2019 Q2 earnings Read more ...
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2019 Results Earnings Conference Call August 05, 2019, 08:30 AM ET Company Participants Mark Donohue - Vice President of Investor Relations and Corporate Communications Chirag Patel - Co-Founder, Co-CEO Chintu Patel - Co-Founder, Co-CEO To...
Amneal Pharmaceuticals ( AMRX ) Q2 results : Revenues: $404.6M (-2.2%). More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
IPic Entertainment (NASDAQ: IPIC ) -57% after bankruptcy filing . More news on: iPic Entertainment Inc., GlycoMimetics, Inc., Cars.com Inc., Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ): Q2 Non-GAAP EPS of $0.09 misses by $0.03 ; GAAP EPS of -$0.13 misses by $0.20 . More news on: Amneal Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
‒ Q2 2019 Net Revenue of $405 Million; GAAP Loss per share of $0.13; Combined Adjusted Diluted EPS (1) of $0.09 ‒ ‒ Positive cash flow from operations of $21 million ‒ ‒ Reaffirms Full Year 2019 EBITDA Guidance ‒ ‒ Investor Ca...
Paul Meister Elected Chairman of the Board Investor Call at 8:30 a.m. ET to Discuss Leadership Transition and Second Quarter 2019 Earnings Results Amneal Pharmaceuticals, Inc. (NYSE:AMRX) today announced that its Co-Founders, Chirag Patel and Chintu Patel, have been named Co-Ch...
Alkermes plc ( ALKS +2.9% ) inks an agreement with Amneal Pharmaceuticals LLC ( AMRX +1.6% ) settling the latter's challenge to a U.S. patent covering opioid/alcohol dependence med VIVITROL (naltrexone for extended-release injectable suspension) that expires in 2029. More news on: Al...
Peak Resorts (NASDAQ: SKIS ) +113% on being acquired by Vail Resorts. More news on: Peak Resorts, Inc., Condor Hospitality Trust, Inc., BioXcel Therapeutics, Inc., Stocks on the move, Read more ...
Amneal Pharmaceuticals (NYSE: AMRX ) is up 6% premarket after the launch of its generic version of Pfizer's Lyrica (pregabalin capsules) 25 mg, 50, 75, 100, 150, 200, 225 and 300 mg. More news on: Amneal Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...